G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL)
Elias Jabbour,Susan O'Brien,Koji Sasaki,Deborah A. Thomas,Guillermo Garcia-Manero,Farhad Ravandi,Gautam Borthakur,Nitin Jain,Marina Konopleva,Jovitta Jacob,Rebecca Garris,Jorge E. Cortes,Hagop M. Kantarjian +12 more
TL;DR: A large number of elderly patients with newly-diagnosed B-cell ALL are eligible for the chemotherapy with mini-hyper-CVD + Inotuzumab ozogamicin, and addition of targeted non-myelosuppressive therapy to effective low-intensity chemotherapy might improve outcome.
Journal ArticleDOI
Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia.
Sanam Loghavi,Jonathan L. Curry,Guillermo Garcia-Manero,Keyur P. Patel,Jie Xu,Joseph D. Khoury,Carlos A. Torres-Cabala,Priyadharsini Nagarajan,Phyu P. Aung,Bernard R Gibson,Brandon P. Goodwin,Brent Kelly,Brinda Rao Korivi,L. Jeffrey Medeiros,Victor G. Prieto,Hagop M. Kantarjian,Carlos E. Bueso-Ramos,Michael T. Tetzlaff +17 more
TL;DR: The spectrum for and underscores the protean nature of cutaneous involvement by CMML is expanded and the importance of heightened vigilance when evaluating skin lesions of CMML patients is underscored.
Journal ArticleDOI
Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML
Maro Ohanian,Hagop M. Kantarjian,Gautam Borthakur,Tapan M. Kadia,Marina Konopleva,Guillermo Garcia-Manero,Zeev Estrov,Alessandra Ferrajoli,Koichi Takahashi,Elias Jabbour,Naval Daver,Steven M. Kornblau,William G. Wierda,Jan A. Burger,Kiran Naqvi,Christopher B. Benton,Prithviraj Bose,John R. Eckardt,Farhad Ravandi,Jorge E. Cortes +19 more
TL;DR: The first 13 pts with R/R FLT3+ AML treated with salvage idarubicin (Ida) and high-dose ara-C (HiDAC) followed by crenolanib achieved a CR/CRi response and no dose-limiting toxicities were observed at any of the dose levels explored and there were no dose reductions required.
Journal ArticleDOI
Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia
Andreia A. Canalli,Hui Yang,Sima Jeha,Koyu Hoshino,Blanca Sanchez-Gonzalez,Mark Brandt,Sherry Pierce,Hagop M. Kantarjian,Jean Pierre J. Issa,Guillermo Garcia-Manero +9 more
TL;DR: Differences in DNA methylation of specific molecular pathways may contribute to the prognostic differences known to occur between pediatric and adult patients with ALL.
Journal ArticleDOI
Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation.
Iman Abou Dalle,Hagop M. Kantarjian,Sarah A. Bannon,Rashmi Kanagal-Shamanna,Mark J. Routbort,Keyur P. Patel,Shimin Hu,Kapil N. Bhalla,Guillermo Garcia-Manero,Courtney D. DiNardo +9 more
TL;DR: Bone marrow was hypercellular for age with hyperplastic megakaryopoiesis, Hematoxylin and Eosin, and there was persistent mild trilineage dysplasia with only rare scattered blasts.